MarketCap
Facebook
X
TelegramФармсинтез Income Statement 2007-2026 | LIFE
Annual Income Statement Фармсинтез
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
380 M | 438 M | 372 M | 291 M | 282 M | 724 M | 661 M | 331 M | 378 M | 245 M | 266 M | 412 M | 275 M | 228 M | 180 M | 173 M |
Cost Of Revenue |
299 M | 277 M | 212 M | 262 M | 251 M | 414 M | 271 M | 168 M | 165 M | 155 M | 147 M | 295 M | 170 M | 155 M | 100 M | 93.5 M |
Gross Profit |
80.8 M | 161 M | 160 M | 28.7 M | 31.2 M | 309 M | 390 M | 163 M | 213 M | 90.3 M | 119 M | 117 M | 106 M | 73.8 M | 79.7 M | 79 M |
Gross Profit Ratio |
0.21 | 0.37 | 0.43 | 0.1 | 0.11 | 0.43 | 0.59 | 0.49 | 0.56 | 0.37 | 0.45 | 0.28 | 0.38 | 0.32 | 0.44 | 0.46 |
General and Administrative Expenses |
19.9 M | 33.8 M | 24.1 M | 158 M | 15.5 M | 306 M | 138 M | 50.7 M | 56.7 M | 41.2 M | - | - | 33.3 M | 31.4 M | 30.1 M | 23.2 M |
Selling And Marketing Expenses |
23.8 M | 53.5 M | 43.9 M | 71.9 M | 19.5 M | 39.1 M | 28 M | 32.6 M | 55.3 M | 18 M | - | 52 M | 30.5 M | 26 M | 28.6 M | 23.5 M |
Selling General And Administrative Expenses |
43.7 M | 87.2 M | 68 M | 246 M | 35 M | 345 M | 166 M | 83.3 M | 112 M | 59.2 M | 144 M | 52 M | 63.7 M | 57.5 M | 58.8 M | 46.7 M |
Other Expenses |
188 M | 189 M | 86.8 M | 1.8 B | -43.4 M | 655 M | 445 M | 434 M | 202 M | 204 M | 16.5 M | -88 M | -13.8 M | -7.13 M | -13.7 M | -7.46 M |
Operating Expenses |
248 M | 330 M | 201 M | 2.05 B | -35.5 M | 1.27 B | 968 M | 711 M | 421 M | 280 M | 301 M | 114 M | 63.7 M | 57.5 M | 58.8 M | 46.7 M |
Cost And Expenses |
547 M | 607 M | 413 M | 2.31 B | 215 M | 1.68 B | 1.24 B | 879 M | 586 M | 435 M | -448 M | 409 M | 233 M | 212 M | 159 M | 140 M |
Interest Expense |
41.3 M | 36.4 M | 29.6 M | - | 5.8 M | 4.54 M | 3.17 M | 2.15 M | 2.12 M | 1.86 M | 4.84 M | 3 M | 1.27 M | 3.03 M | 1.63 M | 139 K |
Depreciation And Amortization |
27.5 M | 32 M | 44.4 M | 25.9 M | 54.6 M | 42.6 M | 71.9 M | 31.7 M | 36.2 M | 22.9 M | 27.3 M | 28 M | -13.6 M | -7.13 M | -13.7 M | -7.46 M |
EBITDA |
-140 M | -647 M | -199 M | -192 M | -213 M | -1.01 B | -613 M | -364 M | -160 M | -119 M | -30 M | 31 M | 28 M | 9.26 M | 7.25 M | 24.9 M |
EBITDA Ratio |
-0.37 | -0.73 | -0.98 | -0.66 | 0.13 | -3.81 | -0.8 | -1.57 | -0.42 | -0.52 | -0.11 | 0.08 | 0.1 | 0.04 | 0.04 | 0.14 |
Operating Income |
-167 M | -169 M | -41.4 M | -2.02 B | 66.7 M | -2.88 B | -616 M | -600 M | -208 M | -180 M | -182 M | 3 M | 42 M | 16.4 M | 21 M | 32.3 M |
Operating Income Ratio |
-0.44 | -0.39 | -0.11 | -6.94 | 0.24 | -3.98 | -0.93 | -1.81 | -0.55 | -0.73 | -0.68 | 0.01 | 0.15 | 0.07 | 0.12 | 0.19 |
Income Before Tax |
-209 M | -733 M | -527 M | -2.03 B | 1.81 M | -2.84 B | -945 M | -398 M | -199 M | -153 M | -62.2 M | 28 M | 27 M | 6.23 M | 5.61 M | 24.7 M |
Income Before Tax Ratio |
-0.55 | -1.67 | -1.42 | -6.97 K | 0.01 | -3.93 | -1.43 | -1.2 | -0.53 | -0.63 | -0.23 | 0.07 | 0.1 | 0.03 | 0.03 | 0.14 |
Income Tax Expense |
-1.22 M | -35.9 M | -2.4 M | 217 M | -58 M | -71.3 M | -34.7 M | -43.5 M | 6.02 M | -6.08 M | -7.65 M | 14 M | 7.98 M | -7.82 M | 3.49 M | 7.87 M |
Net Income Ratio |
-0.55 | -1.59 | -1.41 | -6.22 | 0.21 | -3.49 | -1.36 | -1.07 | -0.54 | -0.6 | -0.2 | 0.03 | 0.07 | 0.06 | 0.01 | 0.1 |
Earnings Per Share, EPS |
-0.69 | -2.32 | -1.74 | -6.02 | 0.21 | -9.13 | -5.92 | -2.34 | -1.43 | -1.37 | -0.77 | 0.05 | 0.06 | 0.11 | 0.02 | 0.14 |
EPS Diluted |
-0.69 | -2.32 | -1.74 | -6.02 | 0.2 | -9.13 | -5.92 | -2.34 | -1.43 | -1.37 | -0.77 | 0.05 | 0.06 | 0.11 | 0.02 | 0.14 |
Weighted Average Shares Outstanding |
301 M | 301 M | 301 M | 301 M | 289 M | 276 M | 152 M | 152 M | 143 M | 108 M | 70.7 M | 301 M | 301 M | 125 M | 125 M | 125 M |
All numbers in RUB currency
Quarterly Income Statement Фармсинтез
| 2023-Q2 | 2022-Q4 | 2022-Q2 | 2021-Q4 | 2021-Q2 | 2020-Q4 | 2020-Q2 | 2019-Q4 | 2019-Q2 | 2018-Q4 | 2018-Q2 | 2017-Q4 | 2017-Q2 | 2016-Q4 | 2016-Q2 | 2015-Q4 | 2015-Q2 | 2014-Q4 | 2014-Q2 | 2013-Q4 | 2013-Q2 | 2012-Q4 | 2011-Q4 | 2011-Q2 | 2010-Q4 | 2010-Q2 | 2009-Q4 | 2009-Q2 | 2008-Q4 | 2008-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
172 M | 172 M | 208 M | 216 M | 222 M | 229 M | 142 M | 94.3 M | 197 M | 245 M | 104 M | 380 M | 343 M | 468 M | 193 M | 125 M | 247 M | 189 M | 189 M | 260 M | 46.8 M | 133 M | 206 M | 206 M | 138 M | 138 M | 114 M | 114 M | 90 M | 90 M |
Cost Of Revenue |
119 M | 151 M | 148 M | 166 M | 111 M | 133 M | 78.7 M | 147 M | 115 M | 126 M | 138 M | 120 M | 328 M | 15.9 M | 249 M | 155 M | 293 M | 82.5 M | 82.5 M | 237 M | 32.8 M | 73.7 M | 148 M | 148 M | 84.8 M | 84.8 M | 77.3 M | 77.3 M | 50.1 M | 50.1 M |
Gross Profit |
53.5 M | 20.5 M | 60.3 M | 50.5 M | 111 M | 96.4 M | 63.5 M | -52.7 M | 81.4 M | 119 M | -33.6 M | 260 M | 15.3 M | 453 M | -56.5 M | -30 M | -46.6 M | 106 M | 106 M | 22.4 M | 14 M | 59.5 M | 58.5 M | 58.5 M | 52.8 M | 52.8 M | 36.9 M | 36.9 M | 39.9 M | 39.9 M |
Gross Profit Ratio |
0.31 | 0.119 | 0.29 | 0.233 | 0.498 | 0.42 | 0.447 | -0.559 | 0.414 | 0.486 | -0.323 | 0.684 | 0.045 | 0.966 | -0.293 | -0.241 | -0.189 | 0.563 | 0.563 | 0.086 | 0.299 | 0.447 | 0.284 | 0.284 | 0.384 | 0.384 | 0.323 | 0.323 | 0.443 | 0.443 |
General and Administrative Expenses |
90.5 M | 69.5 M | 41.9 M | 41.9 M | 43.7 M | 46.1 M | 39 M | 55.4 M | 103 M | 118 M | 106 M | 243 M | 331 M | 271 M | 67.3 M | 77.8 M | 84.9 M | 28.3 M | 28.3 M | 106 M | 21.4 M | - | - | - | 16.6 M | 16.6 M | 15.7 M | 15.7 M | 15.1 M | 15.1 M |
Selling And Marketing Expenses |
7.81 M | 15.9 M | 11 M | 29.2 M | 10.9 M | 20.3 M | 18.7 M | 18.4 M | 53.5 M | 61.8 M | 98.8 M | 154 M | 55.3 M | 56.6 M | 47.5 M | 72.5 M | 94.8 M | 27.6 M | 27.6 M | 43.3 M | 15.2 M | - | 26 M | 26 M | 15.2 M | 15.2 M | 13 M | 13 M | 14.3 M | 14.3 M |
Selling General And Administrative Expenses |
98.3 M | 89.4 M | 106 M | 102 M | 319 M | 142 M | 115 M | 89.6 M | 156 M | 200 M | 205 M | 423 M | 386 M | 345 M | 115 M | 170 M | 180 M | 56 M | 56 M | 156 M | 39.9 M | 72 M | 26 M | 26 M | 31.9 M | 31.9 M | 28.7 M | 28.7 M | 29.4 M | 29.4 M |
Other Expenses |
69 M | - | -805 K | -11.7 M | -2.04 M | - | - | 1.76 B | 35.7 M | - | - | - | - | - | - | - | - | 101 M | 101 M | - | - | 8.27 M | -44 M | -44 M | -6.92 M | -6.92 M | -3.56 M | -3.56 M | -6.85 M | -6.85 M |
Operating Expenses |
178 M | 162 M | 126 M | 165 M | 324 M | 178 M | 125 M | 1.85 B | 195 M | 265 M | 362 M | 2.63 B | 483 M | 1.88 B | 784 M | 100 M | 234 M | 211 M | 211 M | 115 M | 173 M | 151 M | 57 M | 57 M | 31.9 M | 31.9 M | 28.7 M | 28.7 M | 29.4 M | 29.4 M |
Cost And Expenses |
297 M | 314 M | 273 M | 331 M | 435 M | 311 M | 204 M | 2 B | 311 M | 391 M | 500 M | 2.75 B | 811 M | 1.9 B | 1.03 B | 255 M | 528 M | 293 M | 293 M | 352 M | 205 M | -224 M | 204 M | 204 M | 117 M | 117 M | 106 M | 106 M | 79.5 M | 79.5 M |
Interest Expense |
- | - | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06 M | 1.06 M | - | - | 2.42 M | 1.5 M | 1.5 M | 634 K | 634 K | 1.52 M | 1.52 M | 817 K | 817 K |
Depreciation And Amortization |
8.23 M | 8.18 M | 11.7 M | 15.9 M | 16 M | 26.3 M | 18.1 M | 419 K | 25.5 M | 27 M | 27.6 M | 21.7 M | 29 M | 34.1 M | 37.8 M | 15.5 M | 16.2 M | 18.1 M | 18.1 M | 20.8 M | 6.76 M | 13.7 M | 14 M | 14 M | -6.82 M | -6.82 M | -3.56 M | -3.56 M | -6.85 M | -6.85 M |
EBITDA |
-38.4 M | -59.3 M | -3.73 M | -442 M | -228 M | -307 M | -90.2 M | -160 M | -32.1 M | 786 M | -1.01 B | -2.59 B | -873 M | -2.62 B | -267 M | -253 M | -265 M | -80.2 M | -80.2 M | -115 M | -22.7 M | -15 M | 15.5 M | 15.5 M | 14 M | 14 M | 4.63 M | 4.63 M | 3.62 M | 3.62 M |
EBITDA Ratio |
-0.223 | -0.345 | -0.258 | -0.457 | -0.888 | -0.241 | -0.305 | -1.69 | -0.163 | 0.354 | -2.11 | -1.38 | -1.28 | -2.73 | 3.97 | -2.03 | -1.07 | -0.425 | -0.425 | -0.444 | -0.486 | -0.113 | 0.075 | 0.075 | 0.102 | 0.102 | 0.041 | 0.041 | 0.04 | 0.04 |
Operating Income |
-125 M | -67.5 M | -65.4 M | -115 M | -213 M | -81.5 M | -61.5 M | -1.91 B | -114 M | 59.9 M | -247 M | -547 M | -468 M | -1.31 B | 727 M | -268 M | -281 M | -104 M | -104 M | -136 M | -29.5 M | -91 M | 1.5 M | 1.5 M | 21 M | 21 M | 8.19 M | 8.19 M | 10.5 M | 10.5 M |
Operating Income Ratio |
-0.723 | -0.393 | -0.315 | -0.531 | -0.96 | -0.355 | -0.433 | -20.2 | -0.578 | 0.244 | -2.37 | -1.44 | -1.36 | -2.8 | 3.77 | -2.16 | -1.14 | -0.551 | -0.551 | -0.525 | -0.63 | -0.683 | 0.007 | 0.007 | 0.152 | 0.152 | 0.072 | 0.072 | 0.116 | 0.116 |
Income Before Tax |
-142 M | -164 M | -34.4 M | -454 M | -262 M | -351 M | -120 M | -1.91 B | -117 M | -41.7 M | -509 M | -1.32 B | -1.52 B | -1.18 B | 488 M | -119 M | -279 M | -99.4 M | -99.4 M | 154 M | -154 M | -31.1 M | 14 M | 14 M | 13.5 M | 13.5 M | 3.11 M | 3.11 M | 2.81 M | 2.81 M |
Income Before Tax Ratio |
-0.822 | -0.956 | -0.165 | -2.1 | -1.18 | -1.53 | -0.843 | -20.3 K | -593 | -0.17 | -4.89 | -3.47 | -4.44 | -2.52 | 2.53 | -0.96 | -1.13 | -0.526 | -0.526 | 0.592 | -3.28 | -0.233 | 0.068 | 0.068 | 0.098 | 0.098 | 0.027 | 0.027 | 0.031 | 0.031 |
Income Tax Expense |
21.8 M | 24.1 M | 22.9 M | -17.1 M | -18.8 M | 20.6 M | -23 M | 141 M | 76.1 M | 10.2 M | 123 M | 53.5 M | 17.8 M | 12.4 M | 24 M | 47.7 M | 4.16 M | 3.01 M | 3.01 M | 1.66 M | 2.21 M | -3.82 M | 7 M | 7 M | 3.99 M | 3.99 M | -3.91 M | -3.91 M | 1.74 M | 1.74 M |
Net Income Ratio |
-0.949 | -0.816 | -0.324 | -2.06 | -1.14 | -1.82 | -0.756 | -18.8 | -0.206 | -0.128 | -3.71 | -2.67 | -4.39 | -2.46 | 2.66 | -0.577 | -1.15 | -0.542 | -0.542 | 0.598 | -3.23 | -0.205 | 0.034 | 0.034 | 0.069 | 0.069 | 0.061 | 0.061 | 0.012 | 0.012 |
Earnings Per Share, EPS |
-0.54 | -0.48 | -0.22 | -1.48 | -0.84 | -1.39 | -0.36 | -6.1 | -0.13 | -0.107 | -1.28 | -4.04 | -5 | -7.6 | 3.38 | -0.48 | -1.88 | -0.715 | -0.715 | 1.26 | -1.64 | -0.38 | 0.023 | 0.023 | 0.032 | 0.032 | 0.055 | 0.055 | 0.009 | 0.009 |
EPS Diluted |
-0.54 | -0.48 | -0.22 | -1.48 | -0.84 | -1.39 | -0.36 | -6.1 | -0.13 | -0.105 | -1.28 | -4.04 | -5 | -7.6 | 3.38 | -0.48 | -1.88 | -0.715 | -0.715 | 1.26 | -1.64 | -0.38 | 0.023 | 0.023 | 0.032 | 0.032 | 0.055 | 0.055 | 0.009 | 0.009 |
Weighted Average Shares Outstanding |
303 M | 295 M | 301 M | 301 M | 301 M | 301 M | 298 M | 290 M | 312 M | 294 M | 302 M | 251 M | 301 M | 152 M | 152 M | 152 M | 151 M | 143 M | 143 M | 123 M | 92.5 M | 70.7 M | 301 M | 301 M | 301 M | 301 M | 125 M | 125 M | 125 M | 125 M |
All numbers in RUB currency
The income statement is one of the three key financial reports of a company Фармсинтез (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
Germany
China
USA
France
Britain
Israel
Russia
Spain
Belgium
